Approval based on global Phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung ...

Sanofi and Regeneron’s Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthmaApproval based on global phase 3 program ...

Exploration of key clinical trial data and real-world evidence on dupilumab in asthma and COPD presented at the ERS and CHEST ...

Patients with asthma who were with or without a diagnosis of nasal polyps were found to have results with long-term dupilumab. A study published in Annals of Allergy, Asthma & Immunology found that ...

Please provide your email address to receive an email when new articles are posted on . Dupilumab users had at least 0.5 fewer exacerbations per person per 1.5 years compared with other biologics.

Please provide your email address to receive an email when new articles are posted on . Dupilumab significantly reduced asthma exacerbations and improved lung function within 2 weeks in children aged ...

Short-term use of oral corticosteroids is associated with an increased risk of sepsis, VTE TRAVERSE trial findings on the efficacy, safety, and OCS-sparring effect of dupilumab for severe ...

The randomized, double-blind, placebo-controlled VOYAGE trial included 408 children aged 6 to 11 years with uncontrolled persistent asthma. A phase 3 trial evaluating the efficacy and safety of ...

NASHVILLE, Tenn. -- Treatment with the biologic dupilumab (Dupixent) was associated with sustained reductions in oral corticosteroid (OCS) use in asthma patients who required both low and high daily ...

Results from the VOYAGE study of dupilumab (Dupixent) showed that the monoclonal antibody significantly reduced exacerbations in children ages 6-11 with uncontrolled moderate-to-severe asthma, ...

A new medication has been added to the treatment options for children with moderate-to-severe asthma. In a late-stage clinical trial, the biologic agent dupilumab reduced the rate of severe asthma ...

In a late-stage clinical trial, the biologic agent dupilumab reduced the rate of severe asthma attacks and improved lung function and asthma control for children ages 6 to 11. The findings of the ...